

CITATION REPORT

List of articles citing

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition

DOI: 10.1186/s40425-019-0648-3
, 2019, 7, 169.

Source: <https://exaly.com/paper-pdf/72106118/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	Pembrolizumab. <i>Reactions Weekly</i> , 2019 , 1765, 262-262	0	
21	Severe mesenteric ischemia with multiple organ failure in a patient previously treated with a humanized monoclonal antibody against programmed death receptor-1 (pembrolizumab), a case of pembrolizumab associated catastrophic antiphospholipid syndrome?. <i>SAGE Open Medical Case Reports</i> , 2020 , 8, 2050313X20972225	0.7	2
20	Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma-An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
19	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 799-804	3.2	13
18	Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect. <i>BMC Cancer</i> , 2020 , 20, 300	4.8	10
17	Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysis. <i>Journal of Immunotherapy</i> , 2022 , 45, 13-24	5	2
16	Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis. <i>European Journal of Hospital Pharmacy</i> , 2021 ,	1.6	1
15	Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab. <i>American Journal of Case Reports</i> , 2020 , 21, e920809	1.3	2
14	A Probable Case of Mirogabalin-Induced Neutropenia. <i>Cureus</i> , 2020 , 12, e10182	1.2	1
13	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 765608	5.3	1
12	Immune-related neutropenia in cancer patients [review]. <i>Oncolog-Hematolog Ro</i> , 2020 , 2, 24	0	
11	Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation. <i>Frontiers in Pharmacology</i> , 2021 , 12, 746853	5.6	6
10	Efficacy and Safety of PD-1/PD-L1 plus CTLA-4 antibodies +/Other Therapies in Lung Cancer: A Systematic Review and Meta-Analysis.		
9	[Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events]. <i>Chinese Journal of Lung Cancer</i> , 2019 , 22, 676-680	0.6	
8	Delayed immune-related neutropenia with hepatitis by pembrolizumab. <i>Immunotherapy</i> , 2021 ,	3.8	1
7	Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review.. <i>Annals of Hematology</i> , 2022 , 101, 1-10	3	6
6	Mechanisms underlying immune-related adverse events during checkpoint immunotherapy. <i>Clinical Science</i> , 2022 , 136, 771-785	6.5	1

- 5 Intravenous immunoglobulin for pembrolizumab-induced bullous pemphigoid-like eruption: A case report. ○
- 4 Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report. **2022**, ○
- 3 Successful Steroid Treatment of Pembrolizumab-induced Agranulocytosis that Developed after Splenectomy in a Patient with Non-small-cell Lung Cancer: A Case Report. **2023**, ○
- 2 Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review. 12, ○
- 1 Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. **2023**, 12, 1833 ○